Mutation of TP53 and Alteration of p14arf Expression in EGFR- and KRAS -Mutated Lung Adenocarcinomas

Micro-Abstract The p14arf protein activates growth suppression by p53 in response to oncogene activation. In a series of 96 lung adenocarcinomas, disruption of the p53/p14arf pathway ( TP53 mutation or decreased p14arf expression, or both) is observed in 18 of 31 EGFR -mutated (58.1%) and 9 of 13 KR...

Full description

Saved in:
Bibliographic Details
Published inClinical lung cancer Vol. 15; no. 2; pp. 124 - 130
Main Authors Cortot, Alexis B, Younes, Mohamad, Martel-Planche, Ghislaine, Guibert, Benoit, Isaac, Sylvie, Souquet, Pierre-Jean, Commo, Frédéric, Girard, Philippe, Fouret, Pierre, Brambilla, Elisabeth, Hainaut, Pierre, Soria, Jean-Charles
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.03.2014
Subjects
EGFR
Hematology, Oncology and Palliative Medicine
KRAS
Lung adenocarcinoma
p14arf
p53
Pulmonary/Respiratory
KRAS
Lung adenocarcinoma
p14 arf
EGFR
p53
p14arf
Online AccessGet full text

Cover

More Information
Summary:Micro-Abstract The p14arf protein activates growth suppression by p53 in response to oncogene activation. In a series of 96 lung adenocarcinomas, disruption of the p53/p14arf pathway ( TP53 mutation or decreased p14arf expression, or both) is observed in 18 of 31 EGFR -mutated (58.1%) and 9 of 13 KRAS -mutated (69.2%) cases, suggesting that inactivation of this pathway is common but not systematic in relation to oncogene activation.
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2013.08.003